Loading...
TrendSpott

TrendSpott

TrendSpott
 
 
Astrazeneca
69.41
+0.30%
 
Recommendation
AZN Astrazeneca
  Login
 
 
Last Price
 
Change
 
69.41
 
+0.30%
 
 

 
Sentiment
 
  Login to display
 
 

69.59

70.8

66

68.99

 
 
1m
3m
6m
1y
 

Summary

  Login to display Astrazeneca (AZN) recommendation from the last 90 days from financial news and social media.
 

Rewards

Rewards

 Earnings are forecast to grow

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

 

Technical Indicators

Technical Indicators

 MACD falls below signal line

 
 

Risk Level

 
TrendSpott
 

Astrazeneca (AZN) has Low Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 
Earnings ×
 

Earnings

3.00
 

TrendSpott

 Above analyst estimates

TrendSpott

 Reported a weak earnings

 
 
Rating ×
 

Rating

5.00
 

TrendSpott

 Upgraded on attractively valued

 
Momentum ×
 

Momentum

3.26
 

TrendSpott

 Has been gaining momentum

 
Activity ×
 

Activity

3.87
 
 
Future ×
 

Future

4.50
 

TrendSpott

 Earnings are forecast to grow

TrendSpott

 Outperform the market

 
 

Analysts Opinion

Analysts opinion is positive and it remained unchanged from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
79%
100%
42%
100%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is extremely ish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
79%
8%
Positive
Negative
69 out of 87
events present
7 out of 87
events present
 

 
Events Calendar
Click for more information
 
February
S
M
T
W
T
F
S
March
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Dividend Declares
2 Month Ago
67.40
-0.71%
 
Upgrade
2 Month Ago
69.59
+0.90%
 
Strong Earnings
2 Month Ago
67.42
+4.75%
 
Investors Activity
3 Month Ago
70.49
-0.56%
 
Capital Raise
3 Month Ago
70.90
+0.14%
 
Top Headlines

this is why astrazeneca (azn) is a great dividend stock. whether its through stocks bonds etfs or other types of securities all investors love seeing their portfolios score big returns. but for income investors generating consistent c

Fri Mar 31, 2023

Potential

astrazeneca kym biosciences complete licensing deal for cancer drug cmg901.

Thu Mar 30, 2023

Activity

astrazeneca axes pneumonia drug pact with aridis. ) scrapped its license agreement with). with the license terminated for ar-320 (suvratoxumab) the ongoing ar-320-003 phase 3 clinical study must be put on hold the company said in an

Wed Mar 29, 2023

Activity

ionis astrazeneca report positive outcomes from eplontersen trial.

Mon Mar 27, 2023

Activity

ionis pharma reports positive 66-week results of eplontersen phase 3 study in attrv-pn. (rttnews) - ionis pharmaceuticals inc. (ions) announced positive results from the 66-week analysis of the phase 3 neuro-ttransform study of ionis and astraze

Mon Mar 27, 2023

Activity

astrazeneca (azn) could be a great choice. whether its through stocks bonds etfs or other types of securities all investors love seeing their portfolios score big returns. but when youre an income investor your primary focus is generat

Wed Mar 15, 2023

Potential

astrazeneca (azn) gains as market dips: what you should know. astrazeneca (azn) closed at $65.18 in the latest trading session marking a 1.54% move from the prior day. this move outpaced the s&.p 500s daily loss of 0.15%. elsewhere

Mon Mar 13, 2023

Momentum

astrazeneca (azn) posts positive data from lung cancer studies. astrazeneca azn reported positive high-level results from multiple late-stage studies evaluating its blockbuster cancer drugs tagrisso (osimertinib) and imfinzi (durvaluma

Fri Mar 10, 2023

Activity

astrazeneca tagrisso improves overall survival in lung cancer patients in phase 3 trial.

Thu Mar 9, 2023

Activity

astrazeneca says cancer drug imfinzi improves survival rates in late-stage trial. drugmaker astrazeneca said on thursday a late-stage trial showed that imfinzi-based treatment before and after surgery significantly increased the time patients li

Thu Mar 9, 2023

Activity

astrazeneca says cancer drug imfinzi improves survival chances in late-stage trial. lung cancer patients treated with astrazenecas immunotherapy imfinzi pre- and post-surgery in a trial lived significantly longer without the disease progressing

Thu Mar 9, 2023

Activity

ionis astrazeneca eplontersen application accepted by fda for nerve damage disorder.

Tue Mar 7, 2023

Activity

astrazeneca daiichi sankyos enhertu shows promise in multiple cancer types in trial.

Mon Mar 6, 2023

Activity

astrazeneca: enhertu destiny-pantumor02 shows positive results. (rttnews) - british drug maker astrazeneca plc (azn azn.l) and daiichi sankyo (dskyf.pk) announced monday that enhertu (trastuzumab deruxtecan) in destiny-pantumor02 phase ii trial

Mon Mar 6, 2023

Activity

astrazeneca cancer drug enhertu show encouraging initial results for other tumours. astrazeneca said on monday a mid-stage trial of its cancer drug enhertu showed positive results across multiple her2-expressing advanced solid tumours in heavily

Mon Mar 6, 2023

Activity

astrazeneca (azn) shares cross below 200 dma. in trading on thursday shares of astrazeneca plc (symbol: azn) crossed below their 200 day moving average of $64.26 changing hands as low as $64.25 per share. astrazeneca plc shares are currentl

Thu Mar 2, 2023

Momentum

ftse 100 falls as ex-dividend trades weigh. rolls-royce soars. some banks including barclays and standard chartered and healthcare majors astrazeneca and gsk traded without an entitlement for dividend payout

Thu Feb 23, 2023

Activity
Momentum
Momentum

astrazeneca ups gastric cancer effort enters license agreement with kym biosciences for cmg901. (rttnews) - astrazeneca plc (azn.l) a global biopharmaceutical company and kym biosciences inc. have entered into a global exclusive licence agreeme

Thu Feb 23, 2023

Activity

astrazeneca to pay kym $63m upfront in license deal for potential gastric cancer therapy.

Thu Feb 23, 2023

Activity

astrazeneca imfinzi imjudo combo gets approval in eu to treat liver lung cancers.

Wed Feb 22, 2023

Activity

astrazenecas blood cancer drug calquences tablet form gets approval in eu.

Wed Feb 22, 2023

Activity

astrazeneca pt raised to gbp119 at ubs.

Tue Feb 21, 2023

Rating

ex-dividend reminder: astrazeneca steris and baxter international. looking at the universe of stocks we cover at dividend channel on 2/23/23 astrazeneca plc (symbol: azn) steris plc (symbol: ste) and baxter international inc (symbol: bax) wi

Tue Feb 21, 2023

Activity

astrazeneca sophia team up to use ai machine learning in cancer drugs development.

Mon Feb 13, 2023

Activity

astrazeneca (azn) q4 earnings beat sales hurt by covid jab. astrazeneca&rsquo.s azn fourth-quarter 2022 core earnings of 69 cents per american depositary share (ads) beat the zacks consensus estimate of 68 cents. core earnings of $1.38

Thu Feb 9, 2023

Earnings

astrazeneca reports mixed q4 earnings. issues fy23 soft guidance.

Thu Feb 9, 2023

Earnings

astrazeneca trades higher as q4 revenue sans covid products grows. sees sales uptick in fy23.

Thu Feb 9, 2023

Momentum

astrazeneca q4 revenue just shy of analyst estimates. astrazeneca on thursday posted fourth-quarter revenue just shy of analyst estimates with slightly lower-than-expected sales of its best-selling oncology and rare blood disorder drugs.

Thu Feb 9, 2023

Earnings

astrazeneca q4 core earnings beat estimates despite easing covid vaccine demand.

Thu Feb 9, 2023

Earnings

astrazeneca: european commission approves forxiga in treatment of symptomatic chronic heart failure. (rttnews) - astrazeneca (azn azn.l) announced forxiga has been approved in the european union to extend the indication for heart failure with re

Tue Feb 7, 2023

Activity

 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits TrendSpott Rss
 

Receive our daily AZN alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
TrendSpott

TrendSpott

Get the pulse of the market

 
TrendSpott

TrendSpott

AZN Astrazeneca

Last Price
69.41
Change
+0.30%
Recommendation
  Login to display
 

Summary

  Login to display Astrazeneca (AZN) recommendation from the last 90 days from financial news and social media.

 
 
69.59
70.8
66
68.99
 
 
1m
3m
6m
1y
 
Sentiment
 

  Login to display

Rewards

Rewards

 Earnings are forecast to grow

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

Technical Indicators

Technical Indicators

 MACD falls below signal line

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
100%
42%
100%
On Track
On Track
On Track
 
79%
8%
Positive
Negative
69 out of 87
events present
7 out of 87
events present
 

Street Opinion

Street view is extremely ish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 
Earnings ×
 

Earnings

3.00
 

TrendSpott

 Above analyst estimates

TrendSpott

 Reported a weak earnings

 
 
Rating ×
 

Rating

5.00
 

TrendSpott

 Upgraded on attractively valued

 
Momentum ×
 

Momentum

3.26
 

TrendSpott

 Has been gaining momentum

 
Activity ×
 

Activity

3.87
 
 
Future ×
 

Future

4.50
 

TrendSpott

 Earnings are forecast to grow

TrendSpott

 Outperform the market

 
 

Analysts Opinion

Analysts opinion is positive and it remained unchanged from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
TrendSpott
 

Astrazeneca (AZN) has Low Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
February
 
S
M
T
W
T
F
S
 
March
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Dividend Declares
2 Month Ago
67.40
-0.71%
 
Upgrade
2 Month Ago
69.59
+0.90%
 
Strong Earnings
2 Month Ago
67.42
+4.75%
 
Investors Activity
3 Month Ago
70.49
-0.56%
 
Capital Raise
3 Month Ago
70.90
+0.14%
 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits TrendSpott Rss

 

Receive our daily AZN Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines